 |
|
Publication of Clinical Trials in JAMAInformation for Authors
Phil B. Fontanarosa, MD, MBA;
Catherine D. DeAngelis, MD, MPH
JAMA. 2008;299(1):95-96.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Fulfilling the key objective of JAMA, "To promote the science and art of medicine and the betterment of the public health,"1 involves publishing the most important biomedical investigations and clinical research articles possible. Rigorously conducted randomized clinical trials (RCTs) provide the highest level of scientific evidence for interventions and treatment to enable physicians and other practitioners to provide better care for patients and ultimately to improve the health of the public. Therefore, publication of high-quality, major RCTs represents a top priority for JAMA.
JAMA has published a substantial number of major RCTs, including landmark trials that were immediately practice changing2-3; major clinical trials with important practical application and implications4-5; and innovative, cutting-edge trials that have advanced biomedical research.6-7 Although observational studies and systematic reviews also are extremely important and valuable sources of scientific and clinical information, . . . [Full Text of this Article]
Author Affiliations: Dr Fontanarosa (phil.fontanarosa@jama-archives.org) is Executive Deputy Editor and Dr DeAngelis is Editor in Chief, JAMA.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation
Psaty and Kronmal
JAMA 2008;299:1813-1817.
ABSTRACT
| FULL TEXT
|
